Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial
Main Article Content
Keywords
Psoriasis, Calcipotriene, Corticosteroid, Betamethasone, Efficacy
Abstract
Abstract not available.
References
1. Feldman, et al. Am Health Drugs Benefits. 2016:9;504‒513
2. Armstrong, et al. JAMA Dermatol. 2013:149;1180‒1185
3. Bonnekoh, et al. EMJ Dermatol. 2017:5;36‒43
4. EMC. Enstilar Summary of Product Characteristics 2018
5. FDA. Enstilar -Prescribing Information 2019
6. Paul, et al. J EurAcadDermatolVenereol. 2017:31;119‒126
7. Koo, et al. J DermatologTreat. 2016:27;120‒127
2. Armstrong, et al. JAMA Dermatol. 2013:149;1180‒1185
3. Bonnekoh, et al. EMJ Dermatol. 2017:5;36‒43
4. EMC. Enstilar Summary of Product Characteristics 2018
5. FDA. Enstilar -Prescribing Information 2019
6. Paul, et al. J EurAcadDermatolVenereol. 2017:31;119‒126
7. Koo, et al. J DermatologTreat. 2016:27;120‒127